This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Bimatoprost/Timolol Versus Travoprost/Timolol

This study has been completed.
Information provided by (Responsible Party):
Tamer A Macky, Kasr El Aini Hospital Identifier:
First received: February 6, 2012
Last updated: March 1, 2012
Last verified: January 2011
The purpose of this study is to compare 2 fixed combination medications in intraocular pressure lowering.

Condition Intervention
Glaucoma Drug: Ganfort Drug: Duotrav

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Bimatoprost/Timolol Versus Travoprost/Timolol Fixed Combinations in an Egyptian Population: A Hospital-Based Prospective Randomized Study

Resource links provided by NLM:

Further study details as provided by Tamer A Macky, Kasr El Aini Hospital:

Primary Outcome Measures:
  • Percentage of drop of intraocular pressures from baseline. [ Time Frame: 1 year ]

Enrollment: 80
Study Start Date: January 2011
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Glaucoma fixed Combination Medications Drug: Ganfort
Bimatoprost/Timolol fixed combination
Other Name: Bimatoprost/Timolol vs Travoprost/Timolol fixed combination
Drug: Duotrav
Fixed combination of Travoprost and Timolol

Detailed Description:

PURPOSE: To compare the efficacy of bimatoprost/timolol (BTFC) or travoprost/timolol (TTFC) fixed combinations on intraocular pressure (IOP) reduction in an Egyptian population.

METHODS: Patients with primary open angle glaucoma (POAG) were randomized to receive either BTFC or TTFC. IOPs were measured at baseline, 2 weeks, and 1, 2, 4, and 6 months. The primary outcome measures were the mean change in IOP from baseline


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Glaucoma

Exclusion Criteria:

  • No other ocular diseases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01542710

Kasr El Aini Hospital
Cairo, Egypt
Sponsors and Collaborators
Kasr El Aini Hospital
Principal Investigator: Tamer A Macky, MD FRCS Cairo University
  More Information

Responsible Party: Tamer A Macky, Assistant Professor, Kasr El Aini Hospital Identifier: NCT01542710     History of Changes
Other Study ID Numbers: Fixed Glaucoma Medications
GANDUO-2011 ( Other Identifier: Cairo University )
Study First Received: February 6, 2012
Last Updated: March 1, 2012

Additional relevant MeSH terms:
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents processed this record on August 18, 2017